anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
MedDRA terminology has been used to classify the adverse reactions.

Human Experience

In clinical trials and in postmarketing experience, adverse reactions of deliberate or accidental overdosage with oral ABILIFY have been reported worldwide. These include overdoses with ABILIFY alone and in combination with other substances. No fatality was reported with ABILIFY alone. The largest known dose with a known outcome involved acute ingestion of 1,260 mg of ABILIFY (42 times the maximum recommended daily dose) by a patient who fully recovered. Deliberate or accidental overdosage was also reported in children (age 12 years and younger) involving ABILIFY ingestions up to 195 mg with no fatalities.

Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral ABILIFY overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with ABILIFY overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.

Management of Overdosage

No specific information is available on the treatment of overdose with ABILIFY. An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.

Charcoal: In the event of an overdose of ABILIFY, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15 mg dose of ABILIFY, decreased the mean AUC and Cmax of aripiprazole by 50%.

Hemodialysis: Although there is no information on the effect of hemodialysis in treating an overdose with ABILIFY, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.
<P>PROBLEM TO BE SOLVED: To obtain an azulene-containing stable aqueous solution improved in light stability and suppressing generation of insoluble substances, and to obtain a preparation enhanced in transferability of azulenes and berberines to living tissues.  <P>SOLUTION: The aqueous solution is obtained by adding (C) a buffer agent and (D) a nonionic surfactant to an aqueous liquid containing (A) azulenes and (B) berberines. The obtained aqueous solution has improved light stability and excellent long-term stability since the generation of insoluble substances is suppressed. Further, since lipophilicity of azulenes and berberines which are pharmacologically active components is improved, the transferability thereof to the organismic tissue is enhanced. Thus, the aqueous solution is useful as an external preparation, particularly as an ophthalmic preparation.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The utility model provides an insomnia therapeutic instrument relates to the electronic product field. An insomnia therapeutic apparatus comprises a sleep drug releasing component and a sleep music playing component. The sleep drug releasing component and the sleep music playing component are matched with each other to achieve the effect of treating insomnia. The environment and atmosphere created by the use of the two can achieve the effect of treating insomnia. The drug environment (aromatherapy) created by the sleep drug release assembly is relatively durable, and when a user falls asleep, the drug environment does not cause any psychological burden to the user and does not cause any additional influence to the user, so that the user can absorb the drugs in an extremely natural and comfortable environment. The music (five-tone therapy) which is played by the sleep music playing component and is helpful for promoting sleep and the surrounding medicine environment are matched to achieve more remarkable effect of treating insomnia.
BACKGROUND: The post-COVID-19 condition describes the persistence or onset of somatic symptoms (e.g. fatigue) after acute COVID-19. Based on an existing cognitive-behavioral treatment protocol, we developed a specialized group intervention for individuals with post-COVID-19 condition. The present study examines the feasibility, acceptance, and effectiveness of the program for inpatients in a neurological rehabilitation setting.
METHODS: The treatment program comprises eight sessions and includes psychoeducational and experience-based interventions on common psychophysiological mechanisms of persistent somatic symptoms. A feasibility trial was conducted using a one-group design in a naturalistic setting. N = 64 inpatients with a history of mild COVID-19 that fulfilled WHO criteria for post-COVID-19 condition were enrolled. After each session, evaluation forms were completed and psychometric questionnaires on somatic and psychopathological symptom burden were collected pre- and post-intervention.
RESULTS: The treatment program was well received by participants and therapists. Each session was rated as comprehensible and overall satisfaction with the sessions was high. Pre-post effect sizes (of standard rehabilitation incl. new treatment program; intention-to-treat) showed significantly reduced subjective fatigue (p < 0.05, dav = 0.33) and improved disease coping (ps < 0.05, dav = 0.33-0.49).
CONCLUSIONS: Our results support the feasibility and acceptance of the newly developed cognitive-behavioral group intervention for individuals with post-COVID-19 condition. Yet, findings have to be interpreted cautiously due to the lack of a control group and follow-up measurement, the small sample size, and a relatively high drop-out rate.
In-person and written instructions will be given as to how to carry out the breathing retraining at home. Four telephone calls will be made from a member of the research team during the 8-week intervention at weeks 1, 2, 4, and 6. During the phone calls, progress and difficulties related to the breathing intervention will be discussed. A daily log to track performance of the intervention will be kept.
BACKGROUND AND PURPOSE: Sepsis-surviving adult individuals commonly develop immunosuppression and increased susceptibility to secondary infections, an outcome mediated by the axis IL-33/ILC2s/M2 macrophages/Tregs. Nonetheless, the long-term immune consequences of paediatric sepsis are indeterminate. We sought to investigate the role of age in the genesis of immunosuppression following sepsis.
EXPERIMENTAL APPROACH: Here, we compared the frequency of Tregs, the activation of the IL-33/ILC2s axis in M2 macrophages and the DNA methylation of epithelial lung cells from post-septic infant and adult mice. Likewise, sepsis-surviving mice were inoculated intranasally with Pseudomonas aeruginosa or by subcutaneous inoculation of the B16 melanoma cell line. Finally, blood samples from sepsis-surviving patients were collected and the concentration of IL-33 and Tregs frequency were assessed.
KEY RESULTS: In contrast to 6-week-old mice, 2-week-old mice were resistant to secondary infection and did not show impairment in tumour controls upon melanoma challenge. Mechanistically, increased IL-33 levels, Tregs expansion, and activation of ILC2s and M2-macrophages were observed in 6-week-old but not 2-week-old post-septic mice. Moreover, impaired IL-33 production in 2-week-old post-septic mice was associated with increased DNA methylation in lung epithelial cells. Notably, IL-33 treatment boosted the expansion of Tregs and induced immunosuppression in 2-week-old mice. Clinically, adults but not paediatric post-septic patients exhibited higher counts of Tregs and seral IL-33 levels.
CONCLUSION AND IMPLICATIONS: These findings demonstrate a crucial and age-dependent role for IL-33 in post-sepsis immunosuppression. Thus, a better understanding of this process may lead to differential treatments for adult and paediatric sepsis.
NEW MATERIAL:The peptide of formula I (X is Tyr or Phe), formula II (Y is Tyr or Phe), formula III and formula IV, and its salt. EXAMPLE:H-Leu-Ile-Glu-Asp-Asn-Glu-Tyr-Thr-Ala-Arg-Gln-Gly-OH. USE:It has suppressing activities to carrageenin podedema, chemotaxis, etc., and is useful as an antiphlogistic agent. PROCESS:The compound of formula I having carboxy-protecting group and amino- protecting group is prepared by condensing the compound of formula V (R<1> is amino-protecting group; R<2> is carboxy-protecting group) or its salt with the compound of formula VI or its salt according to peptide synthesis process (e.g. acid anhydride process, DCC process, etc.). The protected product can be converted to the compound of formula I by removing the protecting groups with an acid (e.g. trifluoroacetic acid, etc.) preferably in a solvent such as methylene chloride.
Participants in this group are the nearest relatives (or "person-of-trust") of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death.
PURPOSE:To make it possible to measure an antibody antigen in material to be tested simply with higher sensitivity and without nonspecific agglutination by permitting an antigen (antibody) to combine with a functional group on the surface of the outer wall of a microcapsule through a multifunctional bridge formation agent. CONSTITUTION:A microcapsule having a functional group selected from NH2, COOH, OH and SH is formed on the surface by taking as core material biochemically inactive oils and fats. After making a multifunctional bridge formation agent such as glutaric aldehyde to react with a functional group on the surface and an antigen (antibody) is combined to the resultant to sensitize it. The sensitized capsule is dispersed in a physiological saline solution and used for an immune reaction. The sensitized capsule is lyophilized to be kept and can be used at the use by adding water. In this manner a capsule for an immune reaction with higher sensitivity and without nonspecific agglutination can be obtained.
A total of 442 patients with diabetic macular edema will be randomized 1:1 to be treated with either PRO-169 (bevacizumab) or Lucentis® (ranibizumab). There will be a total of 14 visits, including selection and final visits. Monthly evaluations will include ophthalmologic evaluations of anterior and posterior segments, as well as OCT (optic coherence tomography) to obtain central macular width and retinal volume. Fluorescein angiography will be performed on selection visit as well as 6 and 12 months into the study (visits 7 and 13). All patients will be exposed to intravitreal injection of either of the studied drugs monthly for the first 4 months. Starting on visit 5 patients will be injected depending on their response to treatment, calculated according predetermined algorithms including clinical and image variables. Starting on month 6, patients may be subjected to rescue therapy with photocoagulation if they comply with predetermined criteria for such measure.
<P>PROBLEM TO BE SOLVED: To obtain a new peptide that performs high antibacterial effect, cell growth promoting action and bone differentiation inducing action so as to be a substitute for an autologous serum or bovine fetal calf serum and is contained as an active ingredient in a serum-free medium.  <P>SOLUTION: The antimicrobial peptide comprises a specific amino acid sequence. The antifungal agent comprises the peptide. The composition having sterilization and/or growth inhibitory action contains an effective amount of the peptide as an active ingredient. The medical device and apparatus contain the peptide and have antimicrobial property. The method for sterilization and/or growth inhibition of fungi comprises administration of the peptide. The cell growth promoting factor comprises the antimicrobial peptide. The bone differentiation inducing factor comprises the antimicrobial peptide. The serum-free medium comprises the antimicrobial peptide.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain the subject safe medicine containing a specific compound known as an oral cardiotonic medicine, etc., or its derivative as an active ingredient, reduced in side effects, capable of being easily used, and effective for viral infectious diseases such as herpes infectious diseases. SOLUTION: This medicine for cutaneous sensation disorders contains at least one of caffeine of the formula and its derivatives as an active ingredient. The caffeine derivative includes xanthine compounds. The content of the active ingredient in the preparation is usually 5-30%, preferably 10-20%. The preparation can be used in the form of an ointment, cream, scalp agent, lacquer, etc. The caffeine is usually orally administered at a daily dose of 200-900mg in the Japanese pharmacopeia, but the cutaneous sensation disorder medicine is administered at a daily dose of 10-50mg, when coated on skin. Thereby, the medicine is more highly safe than conventional medicines.
Essential for reactive oxygen species (EROS) protein is a recently identified molecular chaperone of NOX2 (gp91phox), the catalytic subunit of phagocyte NADPH oxidase. Deficiency in EROS is a recently identified cause for chronic granulomatous disease, a genetic disorder with recurrent bacterial and fungal infections. Here, we report a cryo-EM structure of the EROS-NOX2-p22phox heterotrimeric complex at an overall resolution of 3.56Å. EROS and p22phox are situated on the opposite sides of NOX2, and there is no direct contact between them. EROS associates with NOX2 through two antiparallel transmembrane (TM) α-helices and multiple β-strands that form hydrogen bonds with the cytoplasmic domain of NOX2. EROS binding induces a 79° upward bend of TM2 and a 48° backward rotation of the lower part of TM6 in NOX2, resulting in an increase in the distance between the two hemes and a shift of the binding site for flavin adenine dinucleotide (FAD). These conformational changes are expected to compromise superoxide production by NOX2, suggesting that the EROS-bound NOX2 is in a protected state against activation. Phorbol myristate acetate, an activator of NOX2 in vitro, is able to induce dissociation of NOX2 from EROS with concurrent increase in FAD binding and superoxide production in a transfected COS-7 model. In differentiated neutrophil-like HL-60, the majority of NOX2 on the cell surface is dissociated with EROS. Further studies are required to delineate how EROS dissociates from NOX2 during its transport to cell surface, which may be a potential mechanism for regulation of NOX2 activation.
Aneuploidy, while detrimental to untransformed cells, is notably prevalent in cancer. Aneuploidy is found as an early event during tumorigenesis which indicates that cancer cells have the ability to surmount the initial stress responses associated with aneuploidy, enabling rapid proliferation despite aberrant karyotypes. To generate more insight into key cellular processes and requirements underlying adaptation to aneuploidy, we generated a panel of aneuploid clones in p53-deficient RPE-1 cells and studied their behavior over time. As expected, de novo-generated aneuploid clones initially display reduced fitness, enhanced levels of chromosomal instability (CIN), and an upregulated inflammatory response. Intriguingly, after prolonged culturing, aneuploid clones exhibit increased proliferation rates while maintaining aberrant karyotypes, indicative of an adaptive response to the aneuploid state. Interestingly, all adapted clones display reduced CIN and reduced inflammatory signaling, suggesting that these are common aspects of adaptation to aneuploidy. Collectively, our data suggests that CIN and concomitant inflammation are key processes that require correction to allow for fast proliferation in vitro. Finally, we provide evidence that amplification of oncogenic KRAS can promote adaptation.
BACKGROUND: Dyslipidaemia, inflammation and elevated Lp(a) levels are associated with the progression of atherosclerosis. This study investigates whether patients with a first-time presentation of chest pain and on-target LDL-C levels and intermediate FRS/ESC-Score risks, display a high inflammatory burden linked to myocardial injury and whether inflammation at admission affects the re-event rate up to 6 years follow-up.
METHODS: Blind assessments of novel inflammatory markers such as Glycoprotein A and B via nuclear magnetic resonance (NMR), cytokines, hsCRP, Neutrophil-to-Lymphocyte ratio (NLR) and Lipoprotein(a) levels were examined. Out of 198 chest pain patients screened, 97 met the inclusion criteria at admission.
RESULTS: cTnI(+) patients (>61 ng/L) with elevated Lipoprotein(a), showed significantly increased levels of Glycoprotein A and B, hsCRP, IL-6, a high NLR and a reduced left ventricular ejection fraction (%) compared to cTnI(-) individuals. Those patients, with a higher inflammatory burden at hospital admission (hsCRP, IL-6, Glycoprotein A and B, and Lipoprotein(a)) had a higher re-event rate at follow-up.
CONCLUSIONS: Inflammation and Lipoprotein(a) levels were particularly prominent in patients presenting with reduced left ventricular ejection fraction. Notably, Glycoproteins A/B emerge as novel markers of inflammation in these patients. Our study highlights the significantly higher impact of inflammatory burden in patients with chest pain and high level of myocardial damage than in those with lower myocardial affectation, even when they all had lipid levels well controlled. Inflammation at the time of admission influenced the re-event rate over a follow-up period of up to 6 years.
This study plans to enroll 20 patients with resectable limited-stage small cell lung cancer in stage T1-3N0-1M0 who have not been treated before. They will receive 3 cycles of adebelimumab combined with chemotherapy and concurrent SBRT. Surgery will be performed within 4-6 weeks after treatment. After surgery, adjuvant therapy will be considered based on the results of MDT discussion. All patients with tumor recurrence and metastasis will enter survival follow-up. Pathological complete response rate (pCR) and safety indexes were used as the main observation indicators.
The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.
Breast invasive carcinoma (BRCA) is the most malignant and leading cause of death in women. Global efforts are ongoing for improvement in early detection, prevention, and treatment. In this milieu, a comprehensive analysis of RNA-sequencing data of 1097 BRCA samples and 114 normal adjacent tissues is done to identify dysregulated genes in major molecular classes of BRCA in various clinical stages. Significantly enriched pathways in distinct molecular classes of BRCA have been identified. Pathways such as interferon signaling, tryptophan degradation, granulocyte adhesion & diapedesis, and catecholamine biosynthesis were found to be significantly enriched in Estrogen/Progesterone Receptor positive/Human Epidermal Growth Factor Receptor 2 negative, pathways such as RAR activation, adipogenesis, the role of JAK1/2 in interferon signaling, TGF-β and STAT3 signaling intricated in Estrogen/Progesterone Receptor negative/Human Epidermal Growth Factor Receptor 2 positive and pathways as IL-1/IL-8, TNFR1/TNFR2, TWEAK, and relaxin signaling were found in triple-negative breast cancer. The dysregulated genes were clustered based on their mutation frequency which revealed nine mutated clusters, some of which were well characterized in cancer while others were less characterized. Each cluster was analyzed in detail which led to the identification of NLGN3, MAML2, TTN, SYNE1, ANK2 as candidate genes in BRCA. They are central hubs in the protein-protein-interaction network, indicating their important regulatory roles. Experimentally, the Real-Time Quantitative Reverse Transcription PCR and western blot confirmed our computational predictions in cell lines. Further, immunohistochemistry corroborated the results in ~ 100 tissue samples. We could experimentally show that the NLGN3 & ANK2 have tumor-suppressor roles in BRCA as shown by cell viability assay, transwell migration, colony forming and wound healing assay. The cell viability and migration was found to be significantly reduced in MCF7 and MDA-MB-231 cell lines in which the selected genes were over-expressed as compared to control cell lines. The wound healing assay also demonstrated a significant decrease in wound closure at 12 h and 24 h time intervals in MCF7 & MDA-MB-231 cells. These findings established the tumor suppressor roles of NLGN3 & ANK2 in BRCA. This will have important ramifications for the therapeutics discovery against BRCA.
<P>PROBLEM TO BE SOLVED: To obtain a moisturizing plant extract with sustainable moisture retaining effect for many hours, an external preparation, a cosmetic, a bathing agent and a detergent composition.  <P>SOLUTION: The moisturizing plant extract comprises an extract of a mixture of Cnidium officinale Makino, Houttuynia cordata Thunberg, Lonicera japonica Thunberg, Schizonepeta tenuifolia Briquet and Rheum palmatum Linne. The cosmetic, the bathing agent and the detergent composition each comprise the extract. The product made by decocting a prescribed ratio of the above-mentioned crude medicine has the same composition as that of a medicine which is called Gomotugedokusan in the traditional Chinese medical science, is used for abscess followed by itch, eczema, etc., and is regarded effective for small rash, eczema, etc., after measles, and hemorrhoid, etc. The extract of the mixture of these crude medicines contains a moisturizing plant component with sustainable moisture retaining effect for many hours and exhibits effects, by external use, on preventing, mitigating or ameliorating dry skin, rough skin, crack, chapped skin, dandruff, itching and inflammatory diseases, and on the hair, in curing dryness, looseness, split hair and broken hair and imparting gloss, and the like.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Participants will be prescribed tabs containing placebo to be taken for 4 weeks and will be monitored by one of thestudy psychiatrists. Subjects randomized placebo will be asked to follow the same pill regimen as subjects randomized to treatment.
The present invention relates to a composition and method for manufacturing a nasal spray solution for the treatment and prevention of COVID-19. The nasal spray solution comprises antibodies obtained from the B cells of COVID-19 patients, wherein the antibodies constitute important active agents for inhibiting SARS-CoV-2. This solution includes a viscosity agent, a tonicity agent, buffers for maintaining the solution's pH within the range of 4-8, a moisturizing agent for nasal tissue, an antimicrobial agent, and deionized water as a solvent. The method for manufacturing the nasal spray solution involves adding water to the foregoing substances, blending them, and keeping the resultant solution at room temperature. Next, antibodies found in the B cells of COVID-19 patients are added to the solution and mixed thoroughly. The solution is further subjected to volume adjustment by using water to obtain 100 milliliters of nasal spray solution for the treatment and prevention of COVID-19. Said nasal spray solution is clear, lacks precipitates and exhibits high stability, all of which are considered beneficial for the treatment and prevention of COVID-19.